Pea F; Viale P, Hallucinations during voriconazole therapy: who is at higher risk and could benefit from therapeutic drug monitoring?, «THERAPEUTIC DRUG MONITORING», 2009, 21, pp. 135 - 136 [Comment or similar]
Pea F; Furlanut M; Viale P, Is antimicrobial underexposure due to glomerular hyperfiltration a possible cause of increased mortality rate from bacterial infections in critically ill patients?, «ANAESTHESIA AND INTENSIVE CARE», 2009, 37, pp. 323 - 324 [Scientific article]
Pea F.; Viale P., Is the minimum inhibitory concentration of vancomycin an infallible predictor of the clinical outcome of staphylococcus aureus bacteremia treated with vancomycin?, «CLINICAL INFECTIOUS DISEASES», 2009, 49, pp. 642 - 643 [Comment or similar]
Pea F., Penetration of antibacterials into bone: What do we really need to know for optimal prophylaxis and treatment of bone and joint infections?, «CLINICAL PHARMACOKINETICS», 2009, 48, pp. 125 - 127 [Comment or similar]
Pea, Federico, [PK/PD profile and post-marketing surveillance of levofloxacin], «LE INFEZIONI IN MEDICINA», 2009, 17 Suppl 5, pp. 13 - 22 [Scientific article]
Pea F.; Furlanut M.; Negri C.; Pavan F.; Crapis M.; Cristini F.; Viale P., Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2009, 53, pp. 1863 - 1867 [Scientific article]
Scaglione F.; Bertazzoni Minelli E.; De Sarro A.; Esposito S.; Legnani D.; Mazzei T.; Mini E.; Passali D.; Pea F.; Stefani S.; Viano I.; Novelli A., The Charta of Milan: Basic criteria for the appropriate and accurate use of antibiotics: Recommendations of the Italian society of chemotherapy, «JOURNAL OF CHEMOTHERAPY», 2009, 21, pp. 475 - 481 [Scientific article]
Viale P.; Furlanut M.; Scudeller L.; Pavan F.; Negri C.; Crapis M.; Zamparini E.; Zuiani C.; Cristini F.; Pea F., Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2009, 33, pp. 379 - 382 [Scientific article]
Pea F; Furlanut M; Viale P, What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2009, 53, pp. 3608 - 3609 [Comment or similar]
Pea F; Furlanut M, Chapter 17 - General considerations in cardiothoracic critical care: importance of pharmacokinetics, in: Core topics in cardiothoracic critical care, USA, Cambridge University Press, 2008, pp. 123 - 126 [Legal Commentary]
Pea F.; Pavan F.; Furlanut M., Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients, «CLINICAL PHARMACOKINETICS», 2008, 47, pp. 449 - 462 [Scientific article]
Pea, F; Tavio, M; Pavan, F; Londero, A; Bresadolo, V; Adani, GL; Furlanut, M; Viale, P, Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients, «ANTIVIRAL THERAPY», 2008, 13, pp. 739 - 742 [Scientific article]
Pea, Federico, [Mutant Prevention Concentration: is it significant in the clinical practice?], «LE INFEZIONI IN MEDICINA», 2008, 16, pp. 12 - 23 [Scientific article]
Pea F.; Baccarani U.; Tavio M.; Cojutti P.; Adani G.L.; Londero A.; Baraldo M.; Franceschi L.; Furlanut M.; Viale P., Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient, «THE ANNALS OF PHARMACOTHERAPY», 2008, 42, pp. 1711 - 1716 [Scientific article]
Pea F.; Viale P., Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?, «CLINICAL PHARMACOKINETICS», 2008, 47, pp. 147 - 152 [Scientific article]
